C4 Therapeutics Inc. outlined its progress in advancing targeted protein degradation (TPD) medicines, with a focus on clinical oncology and discovery programs in inflammation, neuroinflammation, and neurodegeneration $(INN)$ diseases. The company highlighted ongoing and upcoming clinical trials, including the Phase 2 MOMENTUM trial and a Phase 1b trial evaluating cemsidomide in multiple myeloma, as well as the development of CFT8919 for non-small cell lung cancer. Key milestones over the next several years include the completion of clinical trial enrollments, data readouts, initiation of Phase 3 studies, and submission of a New Drug Application (NDA) for cemsidomide. C4 Therapeutics also reported a cash runway expected to extend through the end of 2028. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief on January 20, 2026, and is solely responsible for the information contained therein.